Antibody-Drug Conjugates in Targeted Therapy for Cancer
Pp. 525-537 (13)
Ruoping Tang, Simy Cohen, Ollivier Legrand and Jean-Pierre Marie
An antibody-drug conjugate consists of a potent cytotoxic drug attached to a monoclonal antibody specially targeted on cancer associated antigen. The antigen targeted chemotherapy can improve therapeutic index by increasing potential efficacy and decreasing systemic toxicity. In this review, we described the study and the progress in antibody engineering, the process of drug selection, and the development of linker to optimize the clinical trials. We also discussed about the possible mechanism of cell death induced by an antibody- drug conjugate and the potential resistance to an antibody-drug conjugate. Nonetheless, the successful results from Gentuzumab ozogamicin and other encouraging clinical trials will continue to drive the preclinical development of antibody-drug conjugates.
Université Pierre et Marie Curie; INSERM UMRs 736; Assistance Publique - Hôpitaux de Paris; Hôpital Hôtel Dieu, 1 place du Parvis de Notre-Dame, 75181 Paris cedex 04, France